Showing results (21-30 of 53) with videos related to
Sort By:
Pageof 6
Science (New York, N.Y.)|October 26, 2019
Broadly protective human antibodies that target the active site of influenza virus neuraminidaseDaniel Stadlbauer, Xueyong Zhu, Meagan McMahon, et al.Current Protocols in Microbiology|April 18, 2020
SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test SetupDaniel Stadlbauer, Fatima Amanat, Veronika Chromikova, et al.Nature Communications|July 2, 2025
Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidaseAmanda K Rudman Spergel, Ivan T Lee, Kindra Koslovsky, et al.The Journal of Infectious Diseases|June 27, 2024
Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized TrialJintanat Ananworanich, Ivan T Lee, David Ensz, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 14, 2019
Pre-existing Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally Infected AdultsHannah E Maier, Raffael Nachbagauer, Guillermina Kuan, et al.NPJ Vaccines|March 20, 2021
AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferretsDaniel Stadlbauer, Leon de Waal, Edith Beaulieu, et al.Nature Communications|December 21, 2022
Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation siteDaniel Stadlbauer, Meagan McMahon, Hannah L Turner, et al.Immunohorizons|April 30, 2019
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in MiceAngela Choi, Badiaa Bouzya, Klaus-Daniel Cortés Franco, et al.Nature|November 3, 2020
Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York CityDaniel Stadlbauer, Jessica Tan, Kaijun Jiang, et al.NPJ Vaccines|August 30, 2022
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccinationJohannes B Goll, Aarti Jain, Travis L Jensen, et al.Pageof 6